table of content
1 Study Coverage
1.1 Radiopharmaceuticals in Nuclear Medicine Product Introduction
1.2 Global Radiopharmaceuticals in Nuclear Medicine Outlook 2017 VS 2022 VS 2028
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in US$ Million for the Year 2017-2028
1.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume for the Year 2017-2028
1.3 United States Radiopharmaceuticals in Nuclear Medicine Outlook 2017 VS 2022 VS 2028
1.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales in US$ Million for the Year 2017-2028
1.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales in Volume for the Year 2017-2028
1.4 Radiopharmaceuticals in Nuclear Medicine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Radiopharmaceuticals in Nuclear Medicine in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Radiopharmaceuticals in Nuclear Medicine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
1.5.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
1.5.2 Radiopharmaceuticals in Nuclear Medicine Market Drivers
1.5.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
1.5.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Radiopharmaceuticals in Nuclear Medicine Market Segment by Type
2.1.1 Diagnostic Radiopharmaceuticals
2.1.2 Therapy Radiopharmaceuticals
2.1.3 Enriched Stable Isotopes
2.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type
2.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Radiopharmaceuticals in Nuclear Medicine Market Size by Type
2.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Radiopharmaceuticals in Nuclear Medicine Market Segment by Application
3.1.1 Diagnostic Application
3.1.2 Therapeutic Application
3.1.3 Research
3.1.4 Pharmaceutical
3.1.5 Other
3.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Radiopharmaceuticals in Nuclear Medicine Market Size by Application
3.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Radiopharmaceuticals in Nuclear Medicine Competitor Landscape by Company
4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Company
4.1.1 Top Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Ranked by Revenue (2021)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturer (2017-2022)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturer (2017-2022)
4.1.4 Global Radiopharmaceuticals in Nuclear Medicine Price by Manufacturer (2017-2022)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Concentration Ratio (CR)
4.2.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Radiopharmaceuticals in Nuclear Medicine in 2021
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturing Base Distribution, Product Type
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
4.3.3 Date of International Manufacturers Enter into Radiopharmaceuticals in Nuclear Medicine Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Radiopharmaceuticals in Nuclear Medicine Market Size by Company
4.5.1 Top Radiopharmaceuticals in Nuclear Medicine Players in United States, Ranked by Revenue (2021)
4.5.2 United States Radiopharmaceuticals in Nuclear Medicine Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Radiopharmaceuticals in Nuclear Medicine Sales by Players (2020, 2021 & 2022)
5 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region
5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size in Volume by Region (2017-2028)
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region: 2017-2022
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume Forecast by Region (2023-2028)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size in Value by Region (2017-2028)
5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region: 2017-2022
5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.1.2 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.4.2 Latin America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Bracco Imaging S.P.A.
7.1.1 Bracco Imaging S.P.A. Corporation Information
7.1.2 Bracco Imaging S.P.A. Description and Business Overview
7.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.1.5 Bracco Imaging S.P.A. Recent Development
7.2 Cambridge Isotope Laboratories, Inc.
7.2.1 Cambridge Isotope Laboratories, Inc. Corporation Information
7.2.2 Cambridge Isotope Laboratories, Inc. Description and Business Overview
7.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.2.5 Cambridge Isotope Laboratories, Inc. Recent Development
7.3 Cardinal Health, Inc.
7.3.1 Cardinal Health, Inc. Corporation Information
7.3.2 Cardinal Health, Inc. Description and Business Overview
7.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.3.5 Cardinal Health, Inc. Recent Development
7.4 Covidien, Plc
7.4.1 Covidien, Plc Corporation Information
7.4.2 Covidien, Plc Description and Business Overview
7.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Products Offered
7.4.5 Covidien, Plc Recent Development
7.5 Eczacibasi-Monrol
7.5.1 Eczacibasi-Monrol Corporation Information
7.5.2 Eczacibasi-Monrol Description and Business Overview
7.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Products Offered
7.5.5 Eczacibasi-Monrol Recent Development
7.6 Fujifilm Holdings Corporation
7.6.1 Fujifilm Holdings Corporation Corporation Information
7.6.2 Fujifilm Holdings Corporation Description and Business Overview
7.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Products Offered
7.6.5 Fujifilm Holdings Corporation Recent Development
7.7 GE Healthcare (Subsidiary Of General Electric Company)
7.7.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
7.7.2 GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
7.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Products Offered
7.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Development
7.8 IBA Group
7.8.1 IBA Group Corporation Information
7.8.2 IBA Group Description and Business Overview
7.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Products Offered
7.8.5 IBA Group Recent Development
7.9 Isotec, Inc. (Sigma-Aldrich)
7.9.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
7.9.2 Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
7.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Products Offered
7.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Development
7.10 Lantheus Medical Imaging, Inc.
7.10.1 Lantheus Medical Imaging, Inc. Corporation Information
7.10.2 Lantheus Medical Imaging, Inc. Description and Business Overview
7.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.10.5 Lantheus Medical Imaging, Inc. Recent Development
7.11 Nordion, Inc.
7.11.1 Nordion, Inc. Corporation Information
7.11.2 Nordion, Inc. Description and Business Overview
7.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.11.5 Nordion, Inc. Recent Development
7.12 Ntp Radioisotopes (Pty), Ltd.
7.12.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
7.12.2 Ntp Radioisotopes (Pty), Ltd. Description and Business Overview
7.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Ntp Radioisotopes (Pty), Ltd. Products Offered
7.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Development
7.13 Siemens Healthcare (Subsidiary Of Siemens AG)
7.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
7.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Description and Business Overview
7.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Products Offered
7.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Development
7.14 Taiyo Nippon Sanso Corporation
7.14.1 Taiyo Nippon Sanso Corporation Corporation Information
7.14.2 Taiyo Nippon Sanso Corporation Description and Business Overview
7.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Taiyo Nippon Sanso Corporation Products Offered
7.14.5 Taiyo Nippon Sanso Corporation Recent Development
7.15 Urenco Limited
7.15.1 Urenco Limited Corporation Information
7.15.2 Urenco Limited Description and Business Overview
7.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Urenco Limited Products Offered
7.15.5 Urenco Limited Recent Development
7.16 Rotem Industries, Ltd., Inc.
7.16.1 Rotem Industries, Ltd., Inc. Corporation Information
7.16.2 Rotem Industries, Ltd., Inc. Description and Business Overview
7.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Rotem Industries, Ltd., Inc. Products Offered
7.16.5 Rotem Industries, Ltd., Inc. Recent Development
7.17 Australian Nuclear Association And Technology Organization (ANSTO)
7.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
7.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Description and Business Overview
7.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Products Offered
7.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Development
7.18 Board of Radiation And Isotope Technology (BRIT)
7.18.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
7.18.2 Board of Radiation And Isotope Technology (BRIT) Description and Business Overview
7.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Board of Radiation And Isotope Technology (BRIT) Products Offered
7.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Development
7.19 Institute of Atomic Energy Polatom Radioisotope Centre
7.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
7.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Description and Business Overview
7.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Products Offered
7.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Development
7.20 Institute of Isotopes Co., Ltd.
7.20.1 Institute of Isotopes Co., Ltd. Corporation Information
7.20.2 Institute of Isotopes Co., Ltd. Description and Business Overview
7.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.20.4 Institute of Isotopes Co., Ltd. Products Offered
7.20.5 Institute of Isotopes Co., Ltd. Recent Development
7.21 Institute Of Radioelement (IRE)
7.21.1 Institute Of Radioelement (IRE) Corporation Information
7.21.2 Institute Of Radioelement (IRE) Description and Business Overview
7.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.21.4 Institute Of Radioelement (IRE) Products Offered
7.21.5 Institute Of Radioelement (IRE) Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
8.2 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
8.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
8.4 Radiopharmaceuticals in Nuclear Medicine Sales and Marketing
8.4.1 Radiopharmaceuticals in Nuclear Medicine Sales Channels
8.4.2 Radiopharmaceuticals in Nuclear Medicine Distributors
8.5 Radiopharmaceuticals in Nuclear Medicine Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
